About us

Group overview

Lei Yunshang Group is one of the first batch of China's old brands, state top-secret projects and owners of national intangible cultural heritage, and one of the four major pharmacies. Lei Yun Shang was founded in 1734, and it has been nearly 300 years since then. His founder Lei Dasheng (Ziyun Shang, No. Nanshan, 1696-1779) is a famous doctor of Wumen in Qing Dynasty and a master of Wumen Medical School.

Lei Yunshang Group, with its nearly 300-year-old "Lei Yunshang" as its unified brand and "gathering Baicao Zewanmin" as its mission, upholds the brand idea of "300 years Lei Yunshang, inheriting health wisdom", adheres to the ancestral precept of "Selecting genuine medicinal materials, sticking to their faith, spreading ointment and Dan Shangpin" and inherits and develops the essence of febrile disease theory. At present, it has developed into a large healthy industrial cluster of traditional Chinese medicine, which integrates industry, commerce, chain, traditional Chinese medicine, health preservation and medicinal herbs planting. At present, Leiyunshang Pharmaceutical Group has production bases in Suzhou, Changshu, Shenyang, Changchun, Yunfu, Kunming and other places. The main drug varieties of Leiyunshang Group covers more than 400 quasi-brand products of Chinese medicine, including tablets, powder, granules, pills, capsules and ointments. Among them, there are two national intangible cultural heritage projects (traditional Chinese medicine preparation methods of Leiyunshang Liushen pills and representative inheritors of production techniques of Leiyunshang Liushen pills). Liushen Pills, Jianyingling Capsules and other famous prescriptions of the state's top secret formula products.

At present, Lei Yunshan has eight sales departments: hospital department, investment department, commerce department, general medicine department, OTC department, Pediatrics department, anti-cancer department and nephrology department; five management centers: medicine management center, quality management center, production management center, R&D technology center and finance department. Operating Center. The Group has five subsidiaries directly under it: Lei Yunshang Commercial Company, Lei Yunshang Health Care Company, and more than 50 old shops such as Chanfentang, Wang Hongyi, Mutaishan, etc. with private customized service, such as Lei Yunshang Chinese medicine chain, Changshu Lei Yunshang Pharmaceutical Company and Lei Yunshang Ecological Farm; four member enterprises: Shenyang Lei Yunshang, Mu Taishan, etc. Guangdong Lei Yun Shang, Changchun Lei Yun Shang and Yunnan Lei Yun Shang.

Member enterprises:

Shenyang Yaoda Leiyunshang Pharmaceutical Co., Ltd. used to be a pharmaceutical factory of Shenyang Pharmaceutical University founded in 1958, is a modern joint-stock high-tech enterprise integrating scientific research, production and sales. The company joined in the health cluster of China Grand Enterprises in 2011 and was merged into Leiyunshang Group of China Grand Enterprises in 2014.

For the purpose of overall enterprise development and acceleration of industrial development, a joint decision was made by China Grand Enterprises and Shenyang Pharmaceutical University to relocate the whole company to Benxi City, Liaoning Province, the “Capital of Medicines in China”. In 2014, the company received GMP certification (new edition). In 2017, Antineoplastic Business Department of Leiyunshang Group was established and settled in Shenyang according to the strategic development plan of China Grand Enterprises in an attempt to fully integrate production and sales of all antineoplastic products in the group and establish a professional antineoplastic product sales platform. The company has more than 20 key antineoplastic products, such as brucea jananica oil injection, oxaliplatin, gemcitabine, hydroxycamptothecine, Tianchan capsule, brucea jananica oil oral emulsion, antike capsule, and Tianfoshen oral liquid.

Research and development and innovation

Brucea jananica oil injection, the first microemulsion anti-tumor traditional Chinese medicine injection independently researched, developed and produced by the company, has successively obtained the Second Prize of Provincial Award for Progress in Science and Technology, Gold Award for High-tech, National Protected Variety of Traditional Chinese Medicine, National Invention Patent and other awards and certificates.

The company has been rated as Provincial High-tech Enterprise for more than ten consecutive years since 1998 with four patents. The company won the Second Prize for Shenyang Patent Award in 2013 and the Third Prize for Shenyang Patent Award in 2014. From 2014 to 2016, the company undertook Liaoning Science and Technology Planning Project - “Industrialization of National Class III New Drug Bivalirudin for Injection”.

The company has stuck to the core development concept of innovative research and development, established industry-university-research cooperation platform with Shenyang Pharmaceutical University to research and develop high-end new antineoplastic drugs with clinical value. In the future, the company will conduct a research on all-round full-field high-end liposome. The company will form a unique advantage in technological research and development, technological innovation, achievement transformation and industrialization production so as to achieve the goal of enterprise transformation and science and technology advancement and drive sustainable enterprise development.

Production quality

At present, the company is capable of producing freeze-dried powder injection, small-volume injection, oral emulsion and other preparations. The company values quality, aims to satisfy market demands, pursue higher quality and satisfy customers, constantly optimizes and improves quality management system, improves company product quality and ensures safety and effectiveness of products.

Market sales

Antineoplastic Business Department of Leiyunshang Group has an improved marketing network; moreover, its sales team has strong fighting power and sense of competition; in addition, its sales network is spread over China. Being academic-oriented, the Department has conducted professional promotion and established good collaborative relationship with China Association of Chinese Medicine, World Federation of Chinese Medicine Societies and other academic institutions.

Enterprise tenet

Based on the tenet of being a high-end pharmaceutical enterprise at home and abroad, the company has been dedicated to providing tumor diagnosis, treatment and ancillary drugs in accordance with racial characteristics and improving treatment satisfaction rate and survival rate for Chinese patients with tumors since its foundation.